# aet01_aesi can handle all NA values

    Code
      res
    Output
                                                                                            A: Drug X    B: Placebo    C: Combination
                                                                                             (N=134)       (N=134)        (N=132)    
        —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
        Total number of patients with at least one AE                                      122 (91.0%)   123 (91.8%)    120 (90.9%)  
        Total number of AEs                                                                    609           622            703      
        Total number of patients with at least one AE by worst grade                                                                 
          Grade 1                                                                               0             0              0       
          Grade 2                                                                               0             0              0       
          Grade 3                                                                               0             0              0       
          Grade 4                                                                               0             0              0       
          Grade 5 (fatal outcome)                                                               0             0              0       
        Total number of patients with study drug withdrawn due to AE                            0             0              0       
        Total number of patients with dose modified/interrupted due to AE                       0             0              0       
        Total number of patients with treatment received for AE                                 0             0              0       
        Total number of patients with all non-fatal AEs resolved                                0             0              0       
          No. of patients with study drug withdrawn due to resolved AE                          0             0              0       
          No. of patients with dose modified/interrupted due to resolved AE                     0             0              0       
          No. of patients with treatment received for resolved AE                               0             0              0       
        Total number of patients with at least one unresolved or ongoing non-fatal AE           0             0              0       
          No. of patients with study drug withdrawn due to unresolved or ongoing AE             0             0              0       
          No. of patients with dose modified/interrupted due to unresolved or ongoing AE        0             0              0       
          No. of patients with treatment received for unresolved/ongoing AE                     0             0              0       
        Total number of patients with at least one serious AE                                   0             0              0       
          No. of patients with study drug withdrawn due to serious AE                           0             0              0       
          No. of patients with dose modified/interrupted due to serious AE                      0             0              0       
          No. of patients with treatment received for serious AE                                0             0              0       
        Total number of patients with at least one related AE                                   0             0              0       
          No. of patients with study drug withdrawn due to related AE                           0             0              0       
          No. of patients with dose modified/interrupted due to related AE                      0             0              0       
          No. of patients with treatment received for related AE                                0             0              0       
          No. of patients with serious, related AE                                              0             0              0       

# aet01_aesi can handle some NA values

    Code
      res
    Output
                                                                                            A: Drug X    B: Placebo    C: Combination
                                                                                             (N=134)       (N=134)        (N=132)    
        —————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
        Total number of patients with at least one AE                                      122 (91.0%)   123 (91.8%)    120 (90.9%)  
        Total number of AEs                                                                    609           622            703      
        Total number of patients with at least one AE by worst grade                                                                 
          Grade 1                                                                           7 (5.2%)      9 (6.7%)        4 (3.0%)   
          Grade 2                                                                           6 (4.5%)      10 (7.5%)       7 (5.3%)   
          Grade 3                                                                          18 (13.4%)    14 (10.4%)      16 (12.1%)  
          Grade 4                                                                          15 (11.2%)    20 (14.9%)      18 (13.6%)  
          Grade 5 (fatal outcome)                                                          76 (56.7%)    70 (52.2%)      75 (56.8%)  
        Total number of patients with study drug withdrawn due to AE                       27 (20.1%)    26 (19.4%)      30 (22.7%)  
        Total number of patients with dose modified/interrupted due to AE                  66 (49.3%)    76 (56.7%)      74 (56.1%)  
        Total number of patients with treatment received for AE                            98 (73.1%)    102 (76.1%)    103 (78.0%)  
        Total number of patients with all non-fatal AEs resolved                           20 (14.9%)     13 (9.7%)      13 (9.8%)   
          No. of patients with study drug withdrawn due to resolved AE                          0         1 (0.7%)        2 (1.5%)   
          No. of patients with dose modified/interrupted due to resolved AE                 3 (2.2%)      5 (3.7%)        2 (1.5%)   
          No. of patients with treatment received for resolved AE                           12 (9.0%)     7 (5.2%)        8 (6.1%)   
        Total number of patients with at least one unresolved or ongoing non-fatal AE      102 (76.1%)   110 (82.1%)    107 (81.1%)  
          No. of patients with study drug withdrawn due to unresolved or ongoing AE        27 (20.1%)    25 (18.7%)      28 (21.2%)  
          No. of patients with dose modified/interrupted due to unresolved or ongoing AE   63 (47.0%)    71 (53.0%)      72 (54.5%)  
          No. of patients with treatment received for unresolved/ongoing AE                86 (64.2%)    95 (70.9%)      95 (72.0%)  
        Total number of patients with at least one serious AE                              104 (77.6%)   101 (75.4%)     99 (75.0%)  
          No. of patients with study drug withdrawn due to serious AE                       9 (6.7%)      6 (4.5%)       11 (8.3%)   
          No. of patients with dose modified/interrupted due to serious AE                 22 (16.4%)    26 (19.4%)      29 (22.0%)  
          No. of patients with treatment received for serious AE                           70 (52.2%)    73 (54.5%)      62 (47.0%)  
        Total number of patients with at least one related AE                              105 (78.4%)   108 (80.6%)    109 (82.6%)  
          No. of patients with study drug withdrawn due to related AE                       6 (4.5%)      12 (9.0%)       8 (6.1%)   
          No. of patients with dose modified/interrupted due to related AE                 29 (21.6%)    38 (28.4%)      38 (28.8%)  
          No. of patients with treatment received for related AE                           69 (51.5%)    74 (55.2%)      72 (54.5%)  
          No. of patients with serious, related AE                                         76 (56.7%)    70 (52.2%)      75 (56.8%)  

